Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment
Ray Hachem(The University of Texas MD Anderson Cancer Center), Issam Raad(Missouri Department of Agriculture), Amelia Langston(CancerCare Manitoba), John R. Graybill(Office of Infectious Diseases), Hernando Patino(Merck Biopharma Co., Ltd. (Japan)), Lisa D. Pedicone, John R. Perfect(Duke University)
Cited by 29
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2010|2.7k
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
|New England Journal of Medicine|2007|1.8k
Guidelines for the Management of Intravascular Catheter-Related Infections
|Clinical Infectious Diseases|2001|1.5k